Proteomics International Laboratories Limited (PIQ.AX)
AUD 0.37
(-2.63%)
AUD 0.37
(-2.63%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -7.23 Million AUD | -43.35% |
| 2023 | -6.36 Million AUD | -27.89% |
| 2022 | -4.97 Million AUD | -61.46% |
| 2021 | -3.08 Million AUD | -54.27% |
| 2020 | -1.99 Million AUD | -8.01% |
| 2019 | -1.85 Million AUD | 21.2% |
| 2018 | -2.34 Million AUD | -131.77% |
| 2017 | 7.38 Million AUD | 487.18% |
| 2016 | -1.9 Million AUD | -117.88% |
| 2015 | -875.95 Thousand AUD | -307.1% |
| 2014 | -215.17 Thousand AUD | -1.08% |
| 2013 | -212.87 Thousand AUD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q4 | -3.12 Million AUD | 0.0% |
| 2024 Q2 | -3.93 Million AUD | 0.0% |
| 2024 FY | -8.9 Million AUD | -39.89% |
| 2023 Q1 | -2.01 Million AUD | 42.69% |
| 2023 Q2 | -4.03 Million AUD | -100.0% |
| 2023 FY | -6.36 Million AUD | -27.89% |
| 2023 Q3 | -1.16 Million AUD | 71.17% |
| 2023 Q4 | -4.18 Million AUD | -259.56% |
| 2022 Q2 | -3.18 Million AUD | 0.0% |
| 2022 Q4 | -3.52 Million AUD | -288.94% |
| 2022 FY | -4.97 Million AUD | -61.46% |
| 2022 Q3 | -905.63 Thousand AUD | 71.53% |
| 2021 FY | -3.08 Million AUD | -54.27% |
| 2021 Q1 | -828.49 Thousand AUD | 60.58% |
| 2021 Q2 | -2.11 Million AUD | -155.38% |
| 2021 Q3 | -493.53 Thousand AUD | 76.67% |
| 2021 Q4 | -2.39 Million AUD | -384.62% |
| 2020 FY | -1.99 Million AUD | -8.01% |
| 2020 Q4 | -2.1 Million AUD | -153.69% |
| 2020 Q3 | -828.49 Thousand AUD | 31.65% |
| 2020 Q2 | -1.21 Million AUD | 0.0% |
| 2019 Q1 | -765.92 Thousand AUD | -532.78% |
| 2019 Q4 | -1.53 Million AUD | -99.71% |
| 2019 Q3 | -767.51 Thousand AUD | 49.9% |
| 2019 Q2 | -1.53 Million AUD | -100.0% |
| 2019 FY | -1.85 Million AUD | 21.2% |
| 2018 Q2 | -1.27 Million AUD | -100.0% |
| 2018 Q1 | -639.61 Thousand AUD | -1015.3% |
| 2018 Q4 | -121.04 Thousand AUD | 79.38% |
| 2018 Q3 | -586.91 Thousand AUD | 54.12% |
| 2018 FY | -2.34 Million AUD | -131.77% |
| 2017 Q3 | 1.84 Million AUD | 298.91% |
| 2017 Q2 | -928.73 Thousand AUD | -100.0% |
| 2017 Q4 | 69.88 Thousand AUD | -96.22% |
| 2017 FY | 7.38 Million AUD | 487.18% |
| 2017 Q1 | -464.36 Thousand AUD | -60.23% |
| 2016 Q2 | -1.03 Million AUD | -372.44% |
| 2016 FY | -1.9 Million AUD | -117.88% |
| 2016 Q3 | -477.12 Thousand AUD | 53.88% |
| 2016 Q1 | -218.98 Thousand AUD | 11.23% |
| 2016 Q4 | -289.8 Thousand AUD | 39.26% |
| 2015 FY | -875.95 Thousand AUD | -307.1% |
| 2015 Q1 | - AUD | 0.0% |
| 2015 Q3 | -218.98 Thousand AUD | 19.26% |
| 2015 Q4 | -246.7 Thousand AUD | -12.65% |
| 2015 Q2 | -271.21 Thousand AUD | 0.0% |
| 2014 Q2 | - AUD | 0.0% |
| 2014 Q3 | - AUD | 0.0% |
| 2014 Q4 | - AUD | 0.0% |
| 2014 FY | -215.17 Thousand AUD | -1.08% |
| 2013 FY | -212.87 Thousand AUD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AdAlta Limited | -5.26 Million AUD | -37.44% |
| Acrux Limited | -9.83 Million AUD | 26.464% |
| Amplia Therapeutics Limited | -4.42 Million AUD | -63.426% |
| Biome Australia Limited | -1.91 Million AUD | -277.974% |
| BTC Health Limited | 1.05 Million AUD | 785.268% |
| Chimeric Therapeutics Limited | -12.3 Million AUD | 41.253% |
| CSL Limited | 5.64 Billion AUD | 100.128% |
| Clarity Pharmaceuticals Ltd | -44.8 Million AUD | 83.858% |
| Clinuvel Pharmaceuticals Limited | 49.14 Million AUD | 114.714% |
| Noxopharm Limited | -7.53 Million AUD | 4.027% |
| PharmAust Limited | -6.65 Million AUD | -8.604% |
| Prescient Therapeutics Limited | -7.18 Million AUD | -0.628% |
| PYC Therapeutics Limited | -38.85 Million AUD | 81.389% |
| Race Oncology Limited | -13.38 Million AUD | 45.955% |
| Starpharma Holdings Limited | -15.15 Million AUD | 52.295% |
| EZZ Life Science Holdings Limited | 9.71 Million AUD | 174.425% |
| Botanix Pharmaceuticals Limited | -14.69 Million AUD | 50.805% |
| Memphasys Limited | -2.7 Million AUD | -167.439% |
| Nyrada Inc. | -4.56 Million AUD | -58.575% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -395.608% |
| Telix Pharmaceuticals Limited | - AUD | Infinity% |
| Bio-Gene Technology Limited | -3.06 Million AUD | -136.135% |
| Zelira Therapeutics Limited | -5.93 Million AUD | -21.78% |
| Patrys Limited | -3.53 Million AUD | -104.33% |
| Dimerix Limited | -25.05 Million AUD | 71.143% |
| Neuren Pharmaceuticals Limited | 225.96 Million AUD | 103.2% |
| Orthocell Limited | -11.68 Million AUD | 38.092% |
| Imugene Limited | -140.93 Million AUD | 94.869% |
| Cynata Therapeutics Limited | -8.8 Million AUD | 17.897% |
| Immutep Limited | -44.93 Million AUD | 83.907% |
| Arovella Therapeutics Limited | -7.19 Million AUD | -0.535% |
| Alterity Therapeutics Limited | -19.6 Million AUD | 63.108% |
| Nanollose Limited | -1.24 Million AUD | -478.605% |
| Invex Therapeutics Ltd | -2.13 Million AUD | -238.932% |
| NeuroScientific Biopharmaceuticals Limited | -2.05 Million AUD | -251.633% |
| Island Pharmaceuticals Limited | -2.87 Million AUD | -151.639% |
| Biotron Limited | -5.15 Million AUD | -40.387% |
| Radiopharm Theranostics Limited | -47.2 Million AUD | 84.682% |
| Tissue Repair Ltd | -4.87 Million AUD | -48.311% |
| AnteoTech Limited | -11.72 Million AUD | 38.332% |
| Hexima Limited | -1 Million AUD | -616.882% |
| Paradigm Biopharmaceuticals Limited | -65.11 Million AUD | 88.894% |
| Recce Pharmaceuticals Ltd | -22.05 Million AUD | 67.206% |
| Avecho Biotechnology Limited | -4.58 Million AUD | -57.578% |
| Actinogen Medical Limited | -12.83 Million AUD | 43.675% |
| Immuron Limited | -5.8 Million AUD | -24.658% |
| Argenica Therapeutics Limited | -5.67 Million AUD | -27.513% |